WELIREG™ Available From Onco360
Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
“Onco360 is honored to be included in the Merck specialty pharmacy network for WELIREG,” said Benito Fernandez, Chief Commercial Officer, Onco360. “Onco360 is committed to supporting von Hippel-Lindau patients afflicted with certain associated tumors requiring treatment.”
References
- Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) | Business Wire . Accessed August 2021.
- Von Hippel-Lindau disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program (nih.gov) . Accessed August 2021.
- Kidney and Renal Pelvis Cancer — Cancer Stat Facts . Accessed August 2021. Accessed August 2021.
Media Contact:
Benito Fernandez, Chief Commercial Officer
[email protected]
516-640-1332